X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8042) 8042
Book Chapter (41) 41
Magazine Article (18) 18
Publication (5) 5
Conference Proceeding (4) 4
Dissertation (4) 4
Book Review (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5076) 5076
ursodeoxycholic acid (4892) 4892
male (2706) 2706
gastroenterology & hepatology (2598) 2598
female (2555) 2555
ursodeoxycholic acid - therapeutic use (2490) 2490
adult (1602) 1602
middle aged (1593) 1593
animals (1521) 1521
cholagogues and choleretics - therapeutic use (1081) 1081
aged (941) 941
primary biliary-cirrhosis (939) 939
cholestasis (895) 895
liver (869) 869
ursodeoxycholic acid - pharmacology (839) 839
treatment outcome (736) 736
liver cirrhosis, biliary - drug therapy (714) 714
primary sclerosing cholangitis (696) 696
rats (685) 685
bile acids (654) 654
ursodeoxycholic acid - administration & dosage (631) 631
pharmacology & pharmacy (616) 616
bile (615) 615
ursodiol (600) 600
primary biliary cirrhosis (561) 561
bile acids and salts - metabolism (516) 516
risk factors (499) 499
liver transplantation (498) 498
bile-acids (494) 494
medicine, general & internal (488) 488
gastroenterology and hepatology (474) 474
liver - metabolism (469) 469
liver - pathology (467) 467
therapy (463) 463
liver diseases (459) 459
pregnancy (456) 456
chenodeoxycholic acid (454) 454
disease (443) 443
prognosis (438) 438
deoxycholic acid - analogs & derivatives (436) 436
double-blind (431) 431
time factors (412) 412
biochemistry & molecular biology (402) 402
apoptosis (397) 397
mice (389) 389
follow-up studies (383) 383
cirrhosis (381) 381
adolescent (364) 364
cholelithiasis - drug therapy (363) 363
drug therapy, combination (350) 350
surgery (340) 340
liver - drug effects (339) 339
chenodeoxycholic acid - therapeutic use (331) 331
liver function tests (330) 330
diagnosis (319) 319
natural-history (313) 313
child (312) 312
cholesterol (311) 311
metabolism (310) 310
liver-disease (308) 308
expression (301) 301
acids (293) 293
analysis (289) 289
retrospective studies (289) 289
deoxycholic acid (288) 288
cholelithiasis - therapy (287) 287
placebo-controlled trial (281) 281
care and treatment (278) 278
pediatrics (277) 277
oncology (269) 269
cholangitis, sclerosing - drug therapy (268) 268
cholangitis (267) 267
bile acids and salts - blood (265) 265
transplantation (265) 265
prospective studies (255) 255
disease progression (254) 254
cholagogues and choleretics - administration & dosage (252) 252
gallstones (252) 252
liver cirrhosis, biliary - complications (252) 252
biopsy (246) 246
bile - metabolism (237) 237
ursodeoxycholic acid - metabolism (236) 236
intrahepatic cholestasis (235) 235
dose-response relationship, drug (234) 234
medicine & public health (233) 233
children (232) 232
ursodeoxycholic acid - adverse effects (232) 232
cholestasis - drug therapy (231) 231
recurrence (231) 231
health aspects (230) 230
cholestasis, intrahepatic - drug therapy (229) 229
liver cirrhosis (229) 229
liver cirrhosis, biliary - diagnosis (228) 228
hepatitis (226) 226
oxidative stress (222) 222
dose ursodeoxycholic acid (219) 219
immunosuppressive agents - therapeutic use (218) 218
cholesterol - metabolism (217) 217
controlled trial (214) 214
double-blind method (213) 213
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7083) 7083
German (297) 297
Japanese (226) 226
French (149) 149
Russian (147) 147
Spanish (105) 105
Chinese (60) 60
Italian (51) 51
Korean (32) 32
Polish (32) 32
Hungarian (19) 19
Dutch (14) 14
Czech (9) 9
Danish (7) 7
Portuguese (7) 7
Ukrainian (7) 7
Turkish (6) 6
Hebrew (5) 5
Swedish (5) 5
Bulgarian (3) 3
Finnish (2) 2
Norwegian (2) 2
Slovak (2) 2
Romanian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 6, pp. 1398 - 1404
[Display omitted] Bile acids (BAs) are major regulators of hepatic BA and lipid metabolism but their mechanisms of action in non-alcoholic fatty liver disease (NAFLD... 
Gastroenterology and Hepatology | 3-hydroxy-3-methylglutaryl-CoA reductase | Stearoyl-CoA desaturase | Non-alcoholic fatty liver disease | Lipogenesis | FGF19 | 3-hydroxy-3-methylglutaryl- CoA reductase | FXR | NONALCOHOLIC STEATOHEPATITIS | AGONISTS | NUCLEAR RECEPTOR | CHOLESTEROL-METABOLISM | TRANSPORT | FEEDBACK-REGULATION | LIVER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Ursodeoxycholic Acid - administration & dosage | Oleic Acid - metabolism | Bile Acids and Salts - biosynthesis | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Intra-Abdominal Fat - metabolism | Obesity, Morbid - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Ursodeoxycholic Acid - pharmacology | Stearoyl-CoA Desaturase - biosynthesis | Liver - drug effects | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Lipid Metabolism - drug effects | Intra-Abdominal Fat - drug effects | Obesity, Morbid - metabolism | Physiological aspects | Obesity | Ursodiol | Deoxycholic acid | Index Medicus | BAs, bile acids | nCEH, neutral cholesterol ester hydrolase | ApoB, apolipoprotein B | LDLR, low density lipoprotein receptor | FGF19, fibroblast growth factor 19 | VLDL, very low density lipoproteins | ABC, ATP-binding cassette | TGs, triglycerides | NAFLD, non-alcoholic fatty liver disease | OA, oleic acid | C4, 7α-hydroxy-4-cholesten-3-one | SHP, small heterodimer partner | SREBP1c, sterol regulatory element-binding protein-1c | CA, cholic acid | PA, palmitic acid | FATP1, fatty acid transport protein 1 | UDCA, ursodeoxycholic acid | FAs, fatty acides | HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase | vWAT, visceral white adipose tissue | SCD, stearoyl-Coa desaturase | CYP7A1, cholesterol 7α-hydroxylase | NASH, non-alcoholic steatohepatitis | FXR, farnesoid X receptor | CDCA, chenodeoxycholic acid | MA, myristic acid | FASN, fatty acid synthase | MTTP, microsomal triglyceride transfer protein | SA, stearic acid | NONALCOHOLIC | FATTY LIVER-DISEASE | Gastroenterology & Hepatology | Endokrinologi och diabetes | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | COA DESATURASE | Endocrinology and Diabetes
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 58, Issue 1, pp. 155 - 168
Summary Bile acid (BA) transporters are critical for maintenance of the enterohepatic BA circulation where BAs exert their multiple physiological functions including stimulation of bile flow, intestinal absorption... 
Gastroenterology and Hepatology | Gallstones | Liver cancer | Bile acids | Fatty liver disease | Cholestasis | Liver regeneration | RAT-LIVER | SALT EXPORT PUMP | GROWTH-FACTOR 19 | ORGANIC ANION TRANSPORTERS | 90-PERCENT PARTIAL-HEPATECTOMY | URSODEOXYCHOLIC ACID | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | GASTROENTEROLOGY & HEPATOLOGY | PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS | FAMILIAL INTRAHEPATIC CHOLESTASIS | Animals | Carrier Proteins - metabolism | Cholestasis - metabolism | Membrane Glycoproteins - metabolism | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Liver Diseases - metabolism | Liver Regeneration - physiology | Receptors, Cytoplasmic and Nuclear - metabolism | Drug resistance in microorganisms | Corticosteroids | Glucagon | Calcifediol | Ursodiol | Deoxycholic acid | Epidermal growth factor | Vitamin D | Physiological aspects | Fibroblast growth factors | Alfacalcidol | IBABP (FABP6, ILBP), intestinal bile acid-binding protein, fatty acid-binding protein 6 | PFIC, progressive familial intrahepatic cholestasis | TNFα, tumor necrosis factor α | 3 (human) | SRC2, p160 steroid receptor coactivator | NAFLD, non-alcoholic fatty liver disease | BA, bile acid | bile acid receptor | 8, cholesterol efflux pump, ATP-binding cassette, subfamily G, member 5 | UDCA, ursodeoxycholic acid | LRH-1 (NR5A2), liver receptor homolog-1 | LCA, lithocholic acid | LXRα (NR1H3), liver X receptor alpha | PPARγ (NR1C3), peroxisome proliferator-activated receptor gamma | OSTαβ, organic solute transporter alpha | ABCG5 | AMPK, AMP activated protein kinase | NASH, non-alcoholic steatohepatitis | SHP (NR0B2), short heterodimer partner | OATP1A2 (SLCO1A2, OATP1, OATP-A, SLC21A3), solute carrier organic anion transporter family, member 1A2 | EGFR, epidermal growth factor receptor | IL6, interleukin 6 | TGR5, G protein-coupled bile acid receptor | PH, partial hepatectomy | AE2, anion exchanger 2 | PSC, primary sclerosing cholangitis | OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1 | RARα (NR1B1), retinoic acid receptor alpha | GLP-1, glucagon like peptide 1 | VDR (NR1I1), vitamin D receptor. Please note that for the convenience of better readability and clarity, abbreviations for transporters and nuclear receptors were capitalized throughout this article when symbols were identical for human and rodents | MRP2 (ABCC2), multidrug resistance-associated protein 2, ATP-binding cassette, subfamily C, member 2 | NTCP (SLC10A1), sodium | CAR (NR1I3), constitutive androstane receptor | taurocholate cotransporting polypeptide, solute carrier family 10, member 1 | PPARα (NR1C1), peroxisome proliferator-activated receptor alpha | Review | GR (NR3C1), glucocorticoid receptor | Bile acids, Cholestasis, Fatty liver disease, Gallstones, Liver regeneration, Liver cancer | 19, fibroblast growth factor 15 | Mdr2 | ICP, intrahepatic cholestasis of pregnancy | BRIC, benign recurrent intrahepatic cholestasis | OATP1B3 (SLCO1B3, OATP8, SLC21A8), solute carrier organic anion transporter family, member 1B3 | MRP3 (ABCC3), multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3 | beta | MDR1 (ABCB1), p-glycoprotein, ATP-binding cassette, subfamily B, member 1 | norUDCA, norursodeoxycholic acid | 6-ECDCA, 6-ethylchenodeoxycholic acid | FXR (NR1H4), farnesoid X receptor | BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2 | HNF4α (NR2A1), hepatocyte nuclear factor 4 alpha | PBC, primary biliary cirrhosis | MDR3 (ABCB4), multidrug resistance protein 2 (rodents) | HNF1α, hepatocyte nuclear factor 1 alpha | NR, nuclear receptor | FGF15 | RXRα (NR2B1), retinoid X receptor alpha | PXR (NR1I2), pregnane X receptor | BSEP (ABCB11), bile salt export pump | HCC, hepatocellular carcinoma | MRP4 (ABCC4), multidrug resistance-associated protein 4, ATP-binding cassette, subfamily C, member 4 | TPN, total parenteral nutrition
Journal Article
Journal Article
American journal of physiology: Gastrointestinal and liver physiology, ISSN 1522-1547, 2017, Volume 312, Issue 6, pp. G550 - G558
.... The naturally occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD... 
Inflammatory bowel disease | Epithelium | Barrier function | Bile acid | Cytokine | cytokine | APOPTOSIS | ACTIVATION | PHYSIOLOGY | bile acid | ULCERATIVE-COLITIS | HEALTHY | inflammatory bowel disease | MODELS | INFLAMMATION | epithelium | INTESTINAL BARRIER | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | barrier function | BILE-ACIDS | WATER | Dextran Sulfate | Intestinal Mucosa - metabolism | Ursodeoxycholic Acid - analogs & derivatives | Humans | Colon - drug effects | Male | Intestinal Mucosa - drug effects | Dose-Response Relationship, Drug | Lithocholic Acid - pharmacology | Time Factors | Biotransformation | Colitis - chemically induced | Inflammation Mediators - metabolism | Disease Models, Animal | Bacteria - metabolism | Cytokines - metabolism | Anti-Inflammatory Agents - pharmacology | Colon - pathology | Mice, Inbred C57BL | Gastrointestinal Microbiome | Intestinal Mucosa - microbiology | Colon - metabolism | HT29 Cells | Ursodeoxycholic Acid - pharmacology | Animals | Colitis - microbiology | Colitis - metabolism | Colon - microbiology | Ursodeoxycholic Acid - metabolism | Colitis - prevention & control | Intestinal Mucosa - pathology | Physiological aspects | Inflammation | Colon (Anatomy) | Anti-inflammatory drugs | Deoxycholic acid | Dextran | Metabolites | Analysis | Gastrointestinal diseases | Ursodiol | Sulfates | Mass spectrometry
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 4, pp. 751 - 761.e8
Journal Article
Journal Article
Applied and Environmental Microbiology, ISSN 0099-2240, 05/2018, Volume 84, Issue 10
Journal Article